Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 12/20 | 0.83 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911266 | 1.00 | USP7 (0.83) | USP7JAK3MGLLPRKCIACVR1 | |
| SCHEMBL23911269 | 1.00 | USP7 (0.83) | USP7JAK3MGLLPRKCIACVR1 | |
| SCHEMBL23911274 | 0.92 | USP7 (0.75) | USP7JAK3MGLLACVR1JAK2 | |
| SCHEMBL23911288 | 0.92 | USP7 (0.75) | USP7JAK3MGLLACVR1JAK2 | |
| SCHEMBL23911276 | 0.92 | USP7 (0.75) | USP7JAK3MGLLACVR1JAK2 | |
| SCHEMBL23911108 | 0.91 | USP7 (1.00) | USP7JAK3ROCK2ROCK1MKNK1 | |
| SCHEMBL23911529 | 0.91 | USP7 (1.00) | USP7JAK3ROCK2ROCK1MKNK1 | |
| SCHEMBL23911361 | 0.91 | USP7 (1.00) | USP7JAK3ROCK2ROCK1MKNK1 | |
| Hydrochloric Acid SCHEMBL23911218 | 0.90 | USP7 (0.98) | USP7JAK3ROCK2ROCK1MKNK1 | |
| SCHEMBL23911327 | 0.90 | USP7 (0.76) | USP7JAK3MGLLACVR1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | USP7 1/4885JAK3 3321/4885MGLL 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.